Clinical trial
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
NCT00002093 is registered in ClinicalTrials.gov with Nexstar Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
- Lead sponsor
- Nexstar Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.